Skip to main content
. 2021 Mar 7;43(1):433–444. doi: 10.1080/0886022X.2021.1885444

Table 1.

Comparison of clinical characteristics between eGFR slope ≧ –3 and < –3 mL/min/1.73m2/yr.

Characteristics All (n = 419) eGFR slope ≧ –3 (n = 304) eGFR slope < –3 (n = 115) p
Age (year) 65.9 ± 12.3 67.0 ± 11.9 63.1 ± 13.0 .003
Male gender (%) 61.1 65.1 50.4 .006
Smoking (%) 30.5 29.6 33.0 .495
Diabetes mellitus (%) 56.6 49.3 75.7 <.001
Hypertension (%) 83.1 80.3 90.4 .013
Coronary artery disease (%) 11.2 8.9 17.4 .014
Systolic blood pressure (mmHg) 141.4 ± 21.1 138.7 ± 19.5 148.3 ± 23.5 <.001
Diastolic blood pressure (mmHg) 79.5 ± 12.8 79.2 ± 12.2 80.1 ± 14.3 .552
Laboratory parameters        
 Fasting glucose (mg/dL) 126.4 ± 57.7 119.8 ± 45.2 143.6 ± 79.6 .003
 Triglyceride (mg/dL) 140.5 (96–200.75) 132 (90.5–191.5) 164 (118–240) <.001
 Total cholesterol (mg/dL) 194.5 ± 46.1 190.5 ± 43.6 205.1 ± 50.6 .004
 Hemoglobin (g/dL) 11.7 ± 2.3 12.1 ± 2.3 10.7 ± 2.0 <.001
 Baseline eGFR (mL/min/1.73m2) 26.4 ± 14.1 29.3 ± 14.2 18.9 ± 10.7 <.001
 Calcium-phosphorous product (mg2/dL2) 38.0 ± 8.6 37.2 ± 8.2 40.1 ± 9.1 .002
Echocardiographic parameters        
 LAD (cm) 3.7 ± 0.6 3.7 ± 0.6 4.0 ± 0.6 <.001
 LAD ≧ 4.7 cm (%) 5.3 3.3 10.4 .003
 LVM/BSA (g/m2) 116.8 ± 36.6 112.0 ± 34.9 129.7 ± 37.9 <.001
 LVM/BSA > 115 g/m2 in male and > 95 g/m2 in female (%) 56.6 49.7 74.8 <.001
 LVM/ht2.7 (g/ht2.7) 55.0 ± 18.3 52.3 ± 17.3 62.0 ± 19.0 <.001
 LVM/ht2.7 > 48 g/ht2.7 in male and > 44 g/ht2.7 in female (%) 64.9 59.5 79.1 <.001
 o/p LVM (%) 153.3 ± 49.6 148.3 ± 46.1 166.2 ± 55.7 .001
 o/p LVM > 128% (%) 68.1 64.6 77.0 .016
 LVEF (%) 69.2 ± 10.0 69.6 ± 9.9 68.1 ± 10.2 .171
 LVEF < 50% (%) 4.1 3.9 4.3 .853
Outcome        
 eGFR slope (mL/min/1.73 m2/yr) –2.01 ± 0.15 –0.57 ± 0.09 –5.81 ± 0.27 <.001
 Progression to dialysis (%) 39.6 27.0 73.0 <.001

eGFR: estimated glomerular filtration rate; LAD: left atrial dimension; LVM: left ventricular mass; BSA: body surface area; ht: height; o/p: observed/predicted; LVEF: left ventricular ejection fraction.